ArticleEJNMMI research2019
Preclinical investigations and first-in-human application of
Article in EJNMMI research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 72 citations in OpenAlex.
- Tetrazine-Inorganic chemistry frontiers · 2026Article
- Contemporary opportunities and potential of Auger electron-emitting theranostics.Theranostics · 2026Review
- A Trifunctional, Rare-Earth Theranostic Chelator Platform to Enable Diagnostic Nuclear Imaging, Surgical Resection, and Radiotherapy.Journal of the American Chemical Society · 2025Article
- Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals.EJNMMI radiopharmacy and chemistry · 2025Article
- Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Advances in PSMA-Targeted Radionuclide Therapeutics.Current treatment options in oncology · 2025Review
- Is Copper-61 the New Gallium-68? Automation and Preclinical Proof-of-Concept ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Harnessing Terbium Radioisotopes for Clinical Advancements: A Systematic Review.Nuclear medicine and molecular imaging · 2025Review
- Application of Photoactive Compounds in Cancer Theranostics: Review on Recent Trends from Photoactive Chemistry to Artificial Intelligence.Molecules (Basel, Switzerland) · 2024Review
- Theranostics - a sure cure for cancer after 100 years?Theranostics · 2024Review
- Terbium sisters: current development status and upscaling opportunities.Frontiers in nuclear medicine · 2024Review
- Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside.Theranostics · 2024Review
- The Radiolabeling of [161Tb]-PSMA-617 by a Novel Radiolabeling Method and Preclinical Evaluation by In Vitro/In Vivo Methods.Research square · 2023Article
- Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?EJNMMI radiopharmacy and chemistry · 2023Review
- Preclinical Evaluation of [Molecules (Basel, Switzerland) · 2023Article
- Article
- Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.Theranostics · 2022Review
- Radiolabeled PSMA Inhibitors.Cancers · 2021Review
- First-in-Humans Application ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 4 countries.
Funding
Abstract
backgroundFor almost a decade, terbium radioisotopes have been explored for their potential theragnostic application in nuclear medicine:
results
conclusionsThe results of this study demonstrate the successful preparation and preclinical testing of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.